IMNN — Imunon Inc
NASDAQ · Healthcare · Biotechnology
$1.60
-$0.03 (-1.84%)
Imunon Inc (IMNN) is a biotechnology company listed on NASDAQ. It is led by Stacy R. Lindborg Ph.D., based in 997 Lenox Drive, Lawrenceville, NJ, United States, 08648, with about 20 employees. Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Net income was -$3.4M. IMNN currently screens at market cap $9.2M.
Use this IMNN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMNN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMNN SEC filings page. Lician reads the product cache first so this HTML stays unique to Imunon Inc even when a live quote feed is slow.
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
IMNN Key Statistics
Market Cap
$9.16M
Volume
84,678
Previous Close
$1.59
Day Range
$1.60 – $1.70
EPS
-$1.62
Revenue
$0.00
Net Income
-$18.62M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
20
IMNN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $500.00K | $500.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$18.62M | -$19.51M | -$35.90M | -$20.77M |
| EPS (Diluted) | -$1.62 | -$2.16 | -$5.03 | $0.00 |
Total Assets
$9.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.87M
Operating Cash Flow
-$18.85M
Free Cash Flow
$0.00
Imunon Inc Company Information
- President, CEO & Director
- Stacy R. Lindborg Ph.D.
- Headquarters
- 997 Lenox Drive, Lawrenceville, NJ, United States, 08648
- Website
- imunon.com
- Phone
- 609 896 9100
- IPO / Founded
- 1999-03-01
- Sector
- Healthcare
- Industry
- Biotechnology